Beta-1 adrenergic receptor
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Beta-1 adrenergic receptor as ChEMBL target CHEMBL3252, mapped to UniProt P18090. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Beta-1 adrenergic receptor matters
Beta-1 adrenergic receptor is reviewed as Beta-1 adrenergic receptor (UniProt P18090); the current evidence base includes 19 approved drugs, 378 compounds, and 80 assays, with lead potency reaching pChEMBL 10.4.
Beta-1 adrenergic receptor Sequence length is 466 aa.
Review this target as Beta-1 adrenergic receptor, mapped to UniProt P18090. Sequence length is 466 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 19 approved drugs, 378 compounds, and 80 assays for this target. The dominant activity type is KI. CHEMBL378501 is the current potency anchor at pChEMBL 10.4.
Use CHEMBL378501 as the tractability anchor when discussing potency (pChEMBL 10.4).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Beta-1 adrenergic receptor matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt P18090, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL378501
|
10.4 | Ki | — |
|
|
No preferred name
CHEMBL210309
|
10.2 | Kd | — |
|
|
No preferred name
CHEMBL543955
|
9.6 | Kd | — |
|
|
No preferred name
CHEMBL267375
|
9.3 | Kd | — |
|
|
No preferred name
CHEMBL723
|
9.1 | Ki | Approved |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
LEVOBETAXOLOL
CHEMBL1201274
|
2000 |
|
|
CARVEDILOL
CHEMBL723
|
1995 |
|
|
BETAXOLOL HYDROCHLORIDE
CHEMBL1691
|
1985 |
|
|
BETAXOLOL
CHEMBL423
|
1985 |
|
|
TIMOLOL
CHEMBL499
|
1978 |
|
|
METOPROLOL
CHEMBL13
|
1978 |
|
|
PROPRANOLOL
CHEMBL27
|
1967 |
|
|
ISOPROTERENOL
CHEMBL434
|
1956 |
|
|
NOREPINEPHRINE
CHEMBL1437
|
1950 |
|
|
PRACTOLOL
CHEMBL6995
|
— |